Navigation Links
Preclinical Study Shows CTI's Brostallicin's Cancer-Killing Ability Based on Genetic Profiling
Date:4/14/2008

Data presented at AACR 2008

SAN DIEGO, April 15 /PRNewswire-FirstCall/ -- Systems Medicine LLC (SM), a wholly owned subsidiary of Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC), presented data from a preclinical study demonstrating that the Company's experimental drug candidate, brostallicin, killed colon and ovarian cancer cells regardless of their p53 status. The study, conducted by Cristina Geroni, Ph.D., et al of Nerviano Medical Sciences in Milan, Italy suggests that while brostallicin is more effective in cells with normal p53 status, cells with abnormal or missing p53 are also killed when treated. P53 is a protein that regulates the cell cycle and acts as a tumor suppressor. Patient tumors that have low or absent p53 are less responsive to standard therapy and have a worse prognosis.

"The results of this study support the further clinical development of brostallicin. They also provide deeper insight into brostallicin's context of vulnerability concerning different types of p53 protein, and where it is most effective. In our continued efforts to make cancer more treatable, results like these increase our understanding of cancer and potential therapies, and bring us closer to being able to offer the right drugs to the right patients," said Jeffrey Jacob, CEO of SM.

This study examined brostallicin's effect on cell viability, cell cycle modulation, and the initiation of cell death in cancer cell models with either normal (also referred to as wild-type) or abnormal (mutated or absent) p53 tumor suppressor. These results were supported through tests in animal models, where brostallicin demonstrated a statistically significant effect on suppressing tumor growth. To review the poster and see more detailed information about the study, please go to http://www.celltherapeutics.com/investors_news-updates.htm.

About Brostallicin

Brostallicin, a novel synthetic second-generation DNA minor groove binder, has potent cancer killing activity and has demonstrated synergism in combination with standard cytotoxic agents as well as with newer targeted therapies in preclinical experimental tumor models. Brostallicin binds covalently to DNA within the DNA minor groove, interfering with DNA division and leading to tumor cell death. More than 200 patients have been treated with brostallicin in single-agent and combination studies. Brostallicin had predictable and predominantly hematologic toxicities. Activity was demonstrated in a number of solid tumor types. A phase II study of brostallicin in relapsed/refractory soft tissue sarcoma met its pre-defined activity and safety hurdles and resulted in a first-line phase II study that is currently being conducted by the European Organization for Research and Treatment of Cancer (EORTC).

About Systems Medicine (SM)

In July 2007, CTI acquired Systems Medicine (SM), a privately held oncology company, in a stock-for-stock merger. SM applies a systems biology approach to drug development, combining pharmacogenomics and bioinformatics with experienced preclinical, clinical, and regulatory expertise to find and exploit a specific cancer's 'context of vulnerability.' Specifically, SM defines the molecular and genetic alterations (context) that cause cancer cells to be particularly sensitive (vulnerable) to a drug or combination of drugs -- the 'context of vulnerability'.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.CellTherapeutics.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of brostallicin include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with brostallicin in particular including, without limitation, the potential failure of the preclinical results to predict results in clinical trials, the potential failure of brostallicin to prove safe and effective for treatment of solid tumors particularly ovarian or colon cancers, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, costs of developing, producing and selling brostallicin, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:

Lindsey Jesch

T: 206.272.4347

F: 206.272.4434

E: media@ctiseattle.com

http://www.celltherapeutics.com/media.htm

Investors Contact:

Leah Grant

T: 206.282.7100

F: 206.272.4434

E: invest@ctiseattle.com

http://www.celltherapeutics.com/investors.htm


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
3. Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
6. Isis Reports Preclinical Data Supporting Liver Safety of ISIS 301012
7. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
8. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
9. Tezampanel, TorreyPines Therapeutics Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
10. Telik Announces Presentation of Preclinical Data on Dual Inhibitors of Aurora Kinases and VEGFR2
11. CorNova Preclinical Results of Valecor Platinum(TM) Coronary Stent Studies Presented at TCT 2007 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... April 28, 2016 ... George Phillips und Stephen Schmidt ... ArisGlobal®, ein führender Anbieter cloudbasierter ... heute bekannt, dass neue Führungskräfte zum Team ... sind, die vielfältige Erfahrungen mitbringen.  Dies wird ...
(Date:4/28/2016)... WARSAW, Ind., April 28, 2016 , Net ... a reported basis over the prior year period, and an ... basis , Diluted EPS for the first quarter were ... period, and $2.00 adjusted, an increase of 29.9% over the ... revenue and adjusted earnings guidance for 2016 Zimmer ...
(Date:4/28/2016)... April 28, 2016   Acsis , a leading ... leading IT market research and advisory firm IDC has ... IDC MarketScape: Worldwide Pharmaceutical Track and Trace Software 2016 ... provides an assessment of the capabilities and business strategies ... software market. Logo - http://photos.prnewswire.com/prnh/20160427/360791LOGO ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... Since launching ... national charitable foundation serving the footwear industry, has broken all previous participation records ... 130 companies across 23 states during the months of April and May, the ...
(Date:4/29/2016)... ... April 29, 2016 , ... The American workforce is on ... security. Most importantly, employees are the single most important asset in creating value ... unhappy? , Just under half of American workers are emotionally checked out with ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... that infants born with severe congenital diaphragmatic hernia have better survival rates if ... congenital diaphragmatic hernia (CDH)—a condition where the diaphragm fails to form completely, letting ...
(Date:4/29/2016)... ... April 29, 2016 , ... The Gluten-Free Certification Program ... to announce the launch of the GFCP Scoop in response to ... purpose of the GFCP Scoop site is to keep the gluten-free ...
(Date:4/29/2016)... ... April 29, 2016 , ... For those who skip ... meal to miss. That was among the many new lifestyle diet tips offered by ... Sharon Kleyne Hour® Power of Water® radio show. Bonny and Lawrence noted that because ...
Breaking Medicine News(10 mins):